1. Academic Validation
  2. DOCK7 protects against replication stress by promoting RPA stability on chromatin

DOCK7 protects against replication stress by promoting RPA stability on chromatin

  • Nucleic Acids Res. 2021 Apr 6;49(6):3322-3337. doi: 10.1093/nar/gkab134.
Ming Gao 1 2 Guijie Guo 1 2 Jinzhou Huang 1 2 Xiaonan Hou 3 Hyoungjun Ham 4 Wootae Kim 1 2 Fei Zhao 1 2 Xinyi Tu 1 2 Qin Zhou 1 2 Chao Zhang 1 2 Qian Zhu 1 2 Jiaqi Liu 1 2 Yuanliang Yan 1 2 Zhijie Xu 1 2 Ping Yin 1 2 Kuntian Luo 1 2 John Weroha 3 Min Deng 1 2 Daniel D Billadeau 4 Zhenkun Lou 1 2
Affiliations

Affiliations

  • 1 Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
  • 2 Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
  • 3 Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.
  • 4 Department of Biochemistry and Molecular Biology, Division of Oncology Research, Mayo Clinic, Rochester, MN 55905, USA.
Abstract

RPA is a critical factor for DNA replication and replication stress response. Surprisingly, we found that chromatin RPA stability is tightly regulated. We report that the GDP/GTP exchange factor DOCK7 acts as a critical replication stress regulator to promote RPA stability on chromatin. DOCK7 is phosphorylated by ATR and then recruited by MDC1 to the chromatin and replication fork during replication stress. DOCK7-mediated Rac1/Cdc42 activation leads to the activation of PAK1, which subsequently phosphorylates RPA1 at S135 and T180 to stabilize chromatin-loaded RPA1 and ensure proper replication stress response. Moreover, DOCK7 is overexpressed in ovarian Cancer and depleting DOCK7 sensitizes Cancer cells to camptothecin. Taken together, our results highlight a novel role for DOCK7 in regulation of the replication stress response and highlight potential therapeutic targets to overcome chemoresistance in Cancer.

Figures
Products